Vivo Bio Tech is a preclinical contract research organization that provides drug discovery services, including toxicity and pharmacological studies, and breeds specialized laboratory animals for pharmaceutical and biotech clients.
The company possesses a narrow moat based on regulatory licenses (OECD-GLP, AAALAC) and high switching costs for pharmaceutical clients who require consistent data for long-term drug filings. However, the moat is weakened by low average ROCE (10%) and net margins (5.8%), suggesting that while the infrastructure is specialized, it lacks significant pricing power against large pharma buyers.
Capital has been primarily directed toward expanding infrastructure, specifically a new large animal facility for canine and porcine studies. While this expands the addressable market, the historical return on equity (8.9%) is modest, and the company recently sold land to boost reported profits, indicating a need for non-core gains to support the bottom line.
The company's expansion into large animal facilities proved to be a capital trap, as the modest 8.9% ROE further deteriorated under the weight of increased debt and interest costs. Without the crutch of one-time land sales to mask operational weakness, the thin 5.8% margins vanished when major pharmaceutical clients continued the trend of moving research in-house. The combination of low pricing power and high fixed costs led to a liquidity crunch, as the 1.82x interest coverage provided no margin for error during a cyclical downturn in R&D spending.
RichFakir rates Vivo Bio Tech Ltd's business quality as poor — 30/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Vivo Bio Tech Ltd is trading about 47% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Vivo Bio Tech Ltd is: Not rated. A poor business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of Vivo Bio Tech Ltd's fair value is about ₹26 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →